Gillian M. Fenton, Esq., CLP has been a member of the Licensing Executives Society (LES, USA & Canada) since 1992, and served as the society President in 2020-2021. Gillian’s contributions to LES and to the field of licensing were recognized with the society’s Frank Barnes Award in October, 2022 and with listing in the IAM 300 in October, 2023. She is presently a member of the LES Public Policy Committee and Course Chair for LES’s IP Licensing Basics course.

Gillian has been GSK Special Counsel for Innovation and Government Collaborations for the past 8 years.She supported a wide variety of GSK business development transactions, R&D collaborations and U.S. Government Contracts including GSK Vaccines agreements with NIH/NIAID, BARDA, DARPA, CARB-X and NIIMBL. Gillian also provided transactional legal support for GSK’s Global Health organization, including an asset transfer to The Sabin Vaccine Institute. Prior to joining GSK, Gillian was VP, Associate General Counsel & Chief Intellectual Property Counsel at Emergent BioSolutions Inc., where she founded the IP department and supported all IP aspects of the company’s IPO and subsequent 9 years of growth through M&A in the vaccines, biodefense, and global health fields. Gillian also spent over ten years in private practice at law firms in Boston, MA and Washington, DC.

Education: J.D. cum laude, Suffolk University Law School; B.Sc. Biochemistry, Trinity College.

Admissions: MA, MD, DC.Registered U.S. Patent Attorney.